Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00016224
Status:
COMPLETED
Last Update Posted:
2013-06-18
First Post:
2001-05-06
Brief Title:
Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
Phase II Trial of Thalidomide in Patients With Ovarian Cancer
Status:
COMPLETED
Status Verified Date:
2013-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs such as thalidomide may stop the growth of cancer cells by stopping blood flow to the tumor
PURPOSE Phase II trial to study the effectiveness of thalidomide in treating women who have epithelial ovarian cancer that has not responded to previous therapy
PURPOSE Phase II trial to study the effectiveness of thalidomide in treating women who have epithelial ovarian cancer that has not responded to previous therapy
Detailed Description:
OBJECTIVES
Determine the time to progression of disease in patients with platinum-refractory or resistant ovarian epithelial carcinoma treated with thalidomide
Evaluate the quality of life of patients treated with this regimen
OUTLINE Patients receive oral thalidomide once daily Treatment continues in the absence of disease progression or unacceptable toxicity
Quality of life is assessed at baseline and then every 4 weeks
PROJECTED ACCRUAL A total of 45 patients will be accrued for this study within 9-15 months
Determine the time to progression of disease in patients with platinum-refractory or resistant ovarian epithelial carcinoma treated with thalidomide
Evaluate the quality of life of patients treated with this regimen
OUTLINE Patients receive oral thalidomide once daily Treatment continues in the absence of disease progression or unacceptable toxicity
Quality of life is assessed at baseline and then every 4 weeks
PROJECTED ACCRUAL A total of 45 patients will be accrued for this study within 9-15 months
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-G01-1943 | Registry Identifier | PDQ Physician Data Query | None |
| CDR0000068611 | REGISTRY | None | None |